nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Home nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders
Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO™ from Centers for Medicare and Medicaid Services
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Long-term follow-up for duration of response (DOR) after weekly nab-sirolimus (ABI-009) in patients with advanced malignant perivascular epitlhelioid cell tumors (PEComa): Results from a registrational open-label phase 2 trial, AMPECT
UPDATE — Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Comments

Comments are closed.